Showing 7321-7330 of 9327 results for "".
- Intralesional Cemiplimab Shows High Pathologic Response in Early-Stage CSCChttps://practicaldermatology.com/news/intralesional-cemiplimab-shows-high-pathologic-response-in-early-stage-cscc/2485540/Low-dose intralesional cemiplimab produced high objective and pathologic response rates without treatment-limiting toxicity in patients with early-stage cutaneous squamous cell carcinoma (CSCC), according to “Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma
- Review: Seven HS PROMs Meet COSMIN Standards for Clinical Usehttps://practicaldermatology.com/news/review-seven-hs-proms-meet-cosmin-standards-for-clinical-use/2485535/A new systematic review and meta-analysis found seven clinically useful tools for capturing and analyzing hidradenitis suppurativa (HS)–specific patient-reported outcome measures (PROMs). The review, which included 26 studies a
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- Study: Mycophenolate Mofetil Effective as First-Line Option for Juvenile Localized Sclerodermahttps://practicaldermatology.com/news/study-mycophenolate-mofetil-effective-as-first-line-option-for-juvenile-localized-scleroderma/2485505/A new study comparing methotrexate (MTX) and mycophenolate mofetil (MMF) suggests MMF may offer a comparable alternative with better patient-reported tolerability outcomes. Researchers analyzed data from 114 patients (MTX [n=68
- Doxycycline and Minocycline Show Benefit in OLP Gingival Lesionshttps://practicaldermatology.com/news/doxycycline-and-minocycline-show-benefit-in-olp-gingival-lesions/2485468/A retrospective analysis suggests doxycycline and minocycline may offer an effective systemic option for patients with inflammatory oral lichen planus (OLP) involving the gingiva who fail to respond to topical agents. Study res
- RE-UNITE-PN Launched to Evaluate Nemolizumab in Prurigo Nodularishttps://practicaldermatology.com/news/re-unite-pn-launched-to-evaluate-nemolizumab-in-prurigo-nodularis/2485449/A new international, non-interventional study aims to provide critical real-world data on nemolizumab’s performance in patients with moderate-to-severe prurigo nodularis (PN). The RE-UNITE-PN study (NCT06988618), sponsored by Galderma, is designed to complement pivo
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://practicaldermatology.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Posterhttps://practicaldermatology.com/news/tyk2-inhibitor-envudeucitinib-shows-durable-skin-clearance-qol-gains-poster/2485378/Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at 2026 Winter Clinical
- Dr. James Del Rosso Presents ‘Medicine Chest’ at Winter Clinical 2026https://practicaldermatology.com/news/dr-james-del-rosso-presents-medicine-chest-at-winter-clinical-2026/2485373/James Q. Del Rosso, DO, delivered his annual “What’s New in the Medicine Chest” update at the 2026 Winter Clinical Dermatology Conference, covering new therapies, novel data, and practice-changing pearls spanning from molluscum and hyperhidrosis to vitiligo, lichen planus, and even mastocytosis.<
- Dr. Darrell Rigel Highlights Urgent Skin Cancer Trends at Winter Clinical 2026https://practicaldermatology.com/news/dr-darrell-rigel-highlights-urgent-skin-cancer-trends-at-winter-clinical-2026/2485361/Skin cancer continues its upward trajectory, with new data showing that one in 19 Americans will be diagnosed with melanoma in their lifetime. This alarming statistic headlined a wide-ranging presentation by Darrell S. Rigel, MD, MS, at the 2026 Winter Clinical Dermatology Conference in Hawaii, w